IDXX vs MYGN
Idexx Laboratories Inc. /DE and Myriad Genetics, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | IDXX | MYGN |
|---|---|---|
| Revenue | $4.3B | $824.5M |
| Net income | $1.1B | $-365.9M |
| Gross margin | 61.8% | 69.9% |
| Net margin | 24.6% | −44.4% |
| Return on equity | 66.2% | −68.5% |
| Diluted EPS | $13.08 | −$3.95 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $1.1B | $-151.6M |
| Equity | $1.6B | $368.0M |
| Net debt / equity | 0.17× | −0.08× |
| Current ratio | 1.23× | 2.49× |
| Revenue CAGR 5y | 9.7% | 8.2% |
| Profit CAGR 5y | 12.7% | — |
IDXX bills 5.2× the revenue of MYGN, and MYGN closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | IDXX | MYGN |
|---|---|---|
| FY2025 | $4.3B | $824.5M |
| FY2024 | $3.9B | $837.6M |
| FY2023 | $3.7B | $753.2M |
| FY2022 | $3.4B | $678.4M |
| FY2021 | $3.2B | $690.6M |
| FY2020 | $2.7B | $557.1M |
| FY2019 | $2.4B | $638.6M |
| FY2018 | $2.2B | $851.1M |
| FY2017 | $2.0B | $743.7M |
| FY2016 | $1.8B | $728.7M |
Net income by year
Bottom line
| Fiscal year | IDXX | MYGN |
|---|---|---|
| FY2025 | $1.1B | $-365.9M |
| FY2024 | $887.9M | $-127.3M |
| FY2023 | $845.0M | $-263.3M |
| FY2022 | $679.1M | $-112.0M |
| FY2021 | $744.8M | $-27.2M |
| FY2020 | $581.8M | $-223.6M |
| FY2019 | $427.7M | $-199.5M |
| FY2018 | $377.0M | $4.6M |
| FY2017 | $263.1M | $133.3M |
| FY2016 | $222.0M | $17.4M |
Advertisement
AdSense · Rectangle 336×280
More in this industry